Rockland Trust Co. Cuts Holdings in Merck & Co., Inc. $MRK

Rockland Trust Co. lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 8.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 490,049 shares of the company’s stock after selling 44,914 shares during the quarter. Merck & Co., Inc. comprises 2.5% of Rockland Trust Co.’s portfolio, making the stock its 9th largest holding. Rockland Trust Co.’s holdings in Merck & Co., Inc. were worth $62,971,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Kingdom Financial Group LLC. acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter worth $25,000. Abound Financial LLC acquired a new position in Merck & Co., Inc. in the 4th quarter valued at $26,000. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. in the 4th quarter worth $26,000. High Note Wealth LLC raised its holdings in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. acquired a new position in Merck & Co., Inc. during the 4th quarter worth $31,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Up 0.2%

NYSE MRK opened at $128.61 on Friday. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The firm has a 50-day simple moving average of $123.98 and a 200 day simple moving average of $119.11. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $135.05. The stock has a market cap of $317.64 billion, a PE ratio of 102.89, a PEG ratio of 5.53 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the company posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, research analysts forecast that Merck & Co., Inc. will post 2.77 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. Merck & Co., Inc.’s payout ratio is currently 272.00%.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Recent approvals and label-expansion efforts for KEYTRUDA and ENFLONSIA, together with Merck’s raised 2026 revenue outlook, are reinforcing the investment case. One analysis estimates the shares may still be modestly undervalued after a strong recent run. Merck Could Be Undervalued on Raised Outlook and Approvals
• Positive Sentiment: Positive cancer-drug trial readouts and broader strength across biotechnology and pharmaceutical stocks could support investor interest in Merck’s oncology portfolio and pipeline. These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
• Neutral Sentiment: An industry report identifies continued opportunities in endometrial cancer, including frontline immunotherapy combinations, companion diagnostics and precision therapies. The report highlights Merck as a participant but does not announce a new company-specific deal or result. Endometrial Cancer Market Share Analysis and Industry Trends
• Negative Sentiment: Three Merck executive vice presidents reported selling a combined 86,553 shares for approximately $11.2 million. The transactions reduced their individual holdings by roughly 24% to 62%, which may weigh on sentiment, although insider sales do not necessarily indicate a change in company fundamentals. Chirfi Guindo SEC Form 4 David Michael Williams SEC Form 4 David R. Maraldo SEC Form 4
• Negative Sentiment: Merck is working to diversify beyond KEYTRUDA ahead of its expected 2028 patent expiration. The need for acquisitions, partnerships and new growth platforms underscores the long-term revenue risk associated with the company’s largest product. Merck Is Racing Beyond KEYTRUDA

Insider Activity

In related news, EVP David Michael Williams sold 52,847 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president directly owned 31,716 shares in the company, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Chirfi Guindo sold 15,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total value of $1,965,000.00. Following the completion of the transaction, the executive vice president directly owned 46,613 shares of the company’s stock, valued at approximately $6,106,303. This trade represents a 24.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 86,553 shares of company stock worth $11,177,945. Company insiders own 0.17% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on MRK. Bank of America upped their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Cantor Fitzgerald restated a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Wells Fargo & Company lifted their price target on Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 8th. BMO Capital Markets upped their price target on Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. Thirteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $134.56.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.